CLINICAL RESEARCH: HYPERTROPHIC CARDIOMYOPATHY
Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy
Mark V. Sherrid, MD, FACC*,*,
Ivan Barac, MD*,
William J. McKenna, MD, FACC ,
Perry M. Elliott, MD, FACC,
Shaughan Dickie, DCR,
Lidia Chojnowska, MD, PhD ,
Susan Casey, RN and
Barry J. Maron, MD, FACC
* St. Luke’s-Roosevelt Hospital Center, Columbia University, College of Physicians and Surgeons, New York, New York
St. George’s Hospital Medical School, London, United Kingdom
National Institute of Cardiology, Warsaw, Poland
Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota.
Manuscript received June 23, 2004;
revised manuscript received December 12, 2004,
accepted January 4, 2005.
* Reprint requests and correspondence: Dr. Mark V. Sherrid, St. Luke’s-Roosevelt Hospital Center, College of Physicians and Surgeons, Columbia University, 1000 10th Avenue, 3B-30, New York, New York 10019. (Email: msherrid{at}chpnet.org).
OBJECTIVES: In this study we assessed the long-term efficacy and safety of disopyramide for patients with obstructive hypertrophic cardiomyopathy (HCM).
BACKGROUND: It has been reported that disopyramide may reduce left ventricular outflow gradient and improve symptoms in patients with HCM. However, long-term efficacy and safety of disopyramide has not been shown in a large cohort.
METHODS: Clinical and echocardiographic data were evaluated in 118 obstructive HCM patients treated with disopyramide at 4 HCM treatment centers. Mortality in the disopyramide-treated patients was compared with 373 obstructive HCM patients not treated with disopyramide.
RESULTS: Patients were followed with disopyramide for 3.1 ± 2.6 years; dose 432 ± 181 mg/day (97% also received beta-blockers). Seventy-eight patients (66%) were maintained with disopyramide without the necessity for major non-pharmacologic intervention with surgical myectomy, alcohol ablation, or pacing; outflow gradient at rest decreased from 75 ± 33 to 40 ± 32 mm Hg (p < 0.0001) and mean New York Heart Association functional class from 2.3 ± 0.7 to 1.7 ± 0.6 (p < 0.0001). Forty other patients (34%) could not be satisfactorily managed with disopyramide and required major invasive interventions because of inadequate symptom and gradient control or vagolytic side effects. All-cause annual cardiac death rate between disopyramide and non-disopyramide-treated patients did not differ significantly, 1.4% versus 2.6%/year (p = 0.07). There was also no difference in sudden death rate, 1.0%/year versus 1.8%/year (p = 0.08).
CONCLUSIONS: Two-thirds of obstructed HCM patients treated with disopyramide could be managed medically with amelioration of symptoms and about 50% reduction in subaortic gradient over  3 years. Disopyramide therapy does not appear to be proarrhythmic in HCM and should be considered before proceeding to surgical myectomy or alternate strategies.
|
Abbreviations and Acronyms
| | Diso = disopyramide | | ECG = electrocardiogram/electrocardiographic | | HCM = hypertrophic cardiomyopathy | | LV = left ventricle/ventricular | | NYHA = New York Heart Association | | SAM = systolic anterior motion |
|
This article has been cited by other articles:
|
|
|
|
 
G S Soor, A Luk, E Ahn, J R Abraham, A Woo, A Ralph-Edwards, and J Butany
Hypertrophic cardiomyopathy: current understanding and treatment objectives
J. Clin. Pathol.,
March 1, 2009;
62(3):
226 - 235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Whitten
Systolic Heart Failure in a Patient With Hypertrophic Obstructive Cardiomyopathy: A Potentially Life-Threatening Complication
Crit. Care Nurse,
October 1, 2008;
28(5):
44 - 52.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Steendijk, E Meliga, M Valgimigli, F J Ten Cate, and P W Serruys
Acute effects of alcohol septal ablation on systolic and diastolic left ventricular function in patients with hypertrophic obstructive cardiomyopathy
Heart,
October 1, 2008;
94(10):
1318 - 1322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S R Ommen, P M Shah, and A J Tajik
Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future
Heart,
October 1, 2008;
94(10):
1276 - 1281.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Hosokawa, H. Takano, T. Ohno, M. Takayama, and T. Takano
Impact of Percutaneous Transluminal Septal Myocardial Ablation on Refractory Paroxysmal Atrial Fibrillation in Patients With Hypertrophic Obstructive Cardiomyopathy
Angiology,
July 1, 2008;
59(3):
329 - 334.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. E. Sirak and M. V. Sherrid
Oral Disopyramide for the Acute Treatment of Severe Outflow Obstruction in Hypertrophic Cardiomyopathy in the ICU Setting
Chest,
May 1, 2008;
133(5):
1243 - 1246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Fifer and G. J. Vlahakes
Management of Symptoms in Hypertrophic Cardiomyopathy
Circulation,
January 22, 2008;
117(3):
429 - 439.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Fifer
Most Fully Informed Patients Choose Septal Ablation Over Septal Myectomy
Circulation,
July 10, 2007;
116(2):
207 - 216.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Barac, S. Upadya, R. Pilchik, G. Winson, M. Passick, F. A. Chaudhry, and M. V. Sherrid
Effect of Obstruction on Longitudinal Left Ventricular Shortening in Hypertrophic Cardiomyopathy
J. Am. Coll. Cardiol.,
March 20, 2007;
49(11):
1203 - 1211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Maron, I. Olivotto, A. G. Zenovich, M. S. Link, N. G. Pandian, J. T. Kuvin, S. Nistri, F. Cecchi, J. E. Udelson, and B. J. Maron
Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction
Circulation,
November 21, 2006;
114(21):
2232 - 2239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Y. Ho and C. E. Seidman
A Contemporary Approach to Hypertrophic Cardiomyopathy
Circulation,
June 20, 2006;
113(24):
e858 - e862.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Treatments for Hypertrophic Obstructive Cardiomyopathy
Journal Watch Cardiology,
June 17, 2005;
2005(617):
2 - 2.
[Full Text]
|
|
|
|
